Skip to content
  • All
  • Liver
  • CNS
  • Gut
  • NASH
  • HCC
  • Alzheimers
GANob_ob NASH mouse
FDA approved Madrigal’s Resmetirom (Rezdiffra®) as first drug treatment for MASH. What now?

As a major landmark in drug development for metabolic dysfunction-associated steatohepatitis (MASH; previously known as NASH, nonalcoholic steatohepatitis), the Food and Drug Administration (FDA) recently approved Resmetirom (Rezdiffra®, Madrigal Pharmaceuticals)…

A7S02923_1
Exploring the Future of Drug Combinations: A Deep Dive into In Vivo Synergy Research in Mouse Tumor Models

The world of oncology is ever-evolving, and as researchers and scientists, we are perpetually on the front lines searching for innovative solutions against cancer. One promising direction is the exploration…

muusfoto_IMG08898-farve
Test 4

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris tempor porttitor rhoncus. Duis efficitur lacinia leo, non tincidunt urna gravida rutrum. Donec in eros ultrices, imperdiet tellus nec, aliquam sapien.…

Test 3 test 3 test 3 test 3 test 3 test 3 test 3 test 3 test 3 test 3

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris tempor porttitor rhoncus. Duis efficitur lacinia leo, non tincidunt urna gravida rutrum. Donec in eros ultrices, imperdiet tellus nec, aliquam sapien.…

Test 2

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris tempor porttitor rhoncus. Duis efficitur lacinia leo, non tincidunt urna gravida rutrum. Donec in eros ultrices, imperdiet tellus nec, aliquam sapien.…

muusfoto_IMG08898-farve
Test 1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris tempor porttitor rhoncus. Duis efficitur lacinia leo, non tincidunt urna gravida rutrum. Donec in eros ultrices, imperdiet tellus nec, aliquam sapien.…

Subscribe for

Company updates

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top